Please login to the form below

Jounce

This page shows the latest Jounce news and features for those working in and with pharma, biotech and healthcare.

Celgene cuts back Jounce alliance ahead of BMS merger

Despite the thinning down of the alliance, the news was greeted enthusiastically by Jounce investors, with its shares rising more than 30% on Wednesday. ... Jounce must now deliver positive results from its phase 2 EMERGE clinical trial of vopratelimab

Latest news

Bluebird and Celgene BCMA CAR-T kicks off ASCO

That includes data on Jounce Therapeutics’ ICOS-targeting antibody JTX-2011 which disappointed investors when the ASCO abstract was made public earlier this month, as well as Celldex’ anti-CD27 agonist
Immuno-oncology at ASCO: survival data, combinations and new indications

Standout examples of that this year include Jounce Therapeutics - which fell dramatically after data from a phase I trial of its ICOS agonist antibody JTX-2011 alongside Bristol-Myers Squibb’s
Celgene pays $300m upfront for immunology start-up Delinia

$43.5m and a $2.5bn licensing deal with Jounce for five immuno-oncology candidates.
Jounce bags $225m upfront in Celgene immuno-oncology deal

Celgene has bolstered its immuno-oncology pipeline in an agreement with US biotech Jounce Therapeutics that gives it options on five experimental cancer therapies. ... According to Jounce Celgene was one of several companies trying to close a licensing

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

Deal Watch July 2016

Licensee. Licensor. Headline. Upfront. Equity. Near-term R&D funding. Celgene. Jounce. $2, 561m. ... Jounce Therapeutics/ Celgene. Portfolio and platform of biomarker driven immuno-oncology therapeutics and CDx.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Hugh Cole joins Jounce Therapeutics as chief business officer

US clinical-stage pharmaceutical company Jounce Therapeutics has appointed Hugh Cole as its new chief business officer and head of corporate development. ... We are thrilled to welcome him to Jounce at a critical point in our drug development process.”.
Constellation Pharmaceuticals appoints Jigar Raythatha as CEO

Raythatha re-joins the firm from Jounce Therapeutics where he was chief business officer, leading its business strategy and development since December 2012.
Merck’s Richard Murray joins Jounce as CEO

pembrolizumab. This experience will benefit Jounce, a Cambridge, Massachusetts-based company that specialises in cancer immunotherapies. ... The new CEO sees potential in Jounce, however, with the prospect of cancer immunotherapies an appetising one for

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Healthcare Lead Copywriter: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Medical Editor: Competitive

Healthcare Senior Account Manager: Competitive

Healthcare Account Director: Competitive

Account Director – Creative Healthcare Communications: Competative

PMHub

Add my company

Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story: How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
Three ways AI will change healthcare in the next decade: Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...